Home 2020-04-14T10:16:20+00:00

Innovators in DNA Repair

Cyteir is developing the next generation of synthetic lethal therapies to treat cancer

Learn More

Cyteir Therapeutics is a leader in the discovery and development of novel therapeutics based on the biology of DNA repair and synthetic lethality for the treatment of cancer. Our initial approach takes advantage of DNA damage overload to induce selective self-destruction of cells by targeting disease-induced RAD51 activity.

“The recent approval and development of PARP inhibitors has paved the way for additional novel DNA repair/synthetic lethality therapies to meet unmet clinical needs in cancers.”

Markus Renschler, MD
President and Chief Executive Officer, Cyteir Therapeutics, Inc.